FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC-AI as a starting dose for early AD.
